Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02062359 | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2016 | clinicaltrials |
| NCT01120275 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma | terminated | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2016 | clinicaltrials |
| NCT01557114 | Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma(Mel-Ipi-Rx) | terminated | Phase 1 | 19 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 9, 2016 | clinicaltrials |
| NCT01316692 | Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma | terminated | Phase 2 | 12 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 30, 2016 | clinicaltrials |
| NCT00991991 | Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma | terminated | — | 5 | Case Comprehensive Cancer CenterOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT00897312 | Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease | terminated | — | 7 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Apr 25, 2016 | clinicaltrials |
| NCT00716495 | Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma | terminated | Phase 1 / Phase 2 | 5 | AGIRx Ltd.INDUSTRY | 1 | Apr 22, 2016 | clinicaltrials |
| NCT00613509 | Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma | terminated | Phase 2 | 23 | Sanofi Pasteur, a Sanofi CompanyINDUSTRY | 2 | Apr 14, 2016 | clinicaltrials |
| NCT01700114 | Post-Approval Study of MelaFind | terminated | — | 487 | MELA Sciences, Inc.INDUSTRY | 1 | Mar 11, 2016 | clinicaltrials |
| NCT01730157 | Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases | terminated | Early Phase 1 | 6 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT01200342 | Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2016 | clinicaltrials |
| NCT00673361 | Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma | terminated | Phase 2 | 9 | Duke UniversityOTHER | 0 | Jan 13, 2016 | clinicaltrials |
| NCT00568451 | Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma | terminated | Phase 2 | 12 | Mayo ClinicOTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT00003715 | Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma | terminated | Phase 2 | 425 | AVAX TechnologiesINDUSTRY | 1 | Dec 3, 2015 | clinicaltrials |
| NCT01709162 | Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma | terminated | Phase 2 | 31 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 30, 2015 | clinicaltrials |
| NCT01236573 | Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes | terminated | Phase 1 / Phase 2 | 34 | National Institutes of Health Clinical Center (CC)NIH | 1 | Nov 26, 2015 | clinicaltrials |
| NCT01474551 | Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation | terminated | Phase 2 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 18, 2015 | clinicaltrials |
| NCT00610311 | Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00612222 | Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00704938 | Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer | terminated | Phase 2 | 3 | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00706992 | Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01160445 | Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01273181 | MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes | terminated | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01495572 | Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Oct 15, 2015 | clinicaltrials |
| NCT01783431 | Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells | terminated | Phase 1 | 1 | Medical University of South CarolinaOTHER | 1 | Oct 2, 2015 | clinicaltrials |
| NCT01045915 | Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma(AMEP) | terminated | Phase 1 | 5 | Valerio TherapeuticsINDUSTRY | 3 | Sep 11, 2015 | clinicaltrials |
| NCT00996827 | Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma | terminated | — | 100 | New Mexico Cancer Research AllianceOTHER | 1 | Jun 18, 2015 | clinicaltrials |
| NCT00776945 | Feasibility and Functionality of fPAM Imaging in Melanoma(fPAM) | terminated | — | 2 | Washington University School of MedicineOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01085396 | Use of Fiber-optic Probe for Non-invasive Diagnosis of Melanoma and Assessment of Impact of Ultraviolet (UV) Exposure on Skin | terminated | — | 16 | University of PittsburghOTHER | 1 | May 27, 2015 | clinicaltrials |
| NCT01216436 | Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma | terminated | Phase 1 | 2 | Duke UniversityOTHER | 1 | May 25, 2015 | clinicaltrials |
| NCT02442466 | Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma | terminated | Early Phase 1 | 5 | MelCure SAINDUSTRY | 0 | May 20, 2015 | clinicaltrials |
| NCT00482105 | Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells(DermTech) | terminated | N/A | 7 | University of California, DavisOTHER | 1 | Apr 22, 2015 | clinicaltrials |
| NCT00072189 | A Phase II Study of UCN-01 in Metastatic Melanoma | terminated | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Mar 2, 2015 | clinicaltrials |
| NCT01369888 | Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jan 27, 2015 | clinicaltrials |
| NCT01400451 | Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) | terminated | Phase 1 | 18 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 1, 2015 | clinicaltrials |
| NCT01835184 | Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery | terminated | Phase 1 | 5 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01123304 | Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma | terminated | Phase 1 | 18 | MorphotekINDUSTRY | 1 | Jul 17, 2014 | clinicaltrials |
| NCT01212276 | A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma | terminated | Phase 1 | 18 | MorphotekINDUSTRY | 1 | Jul 16, 2014 | clinicaltrials |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | terminated | Phase 1 | 35 | Yale UniversityOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT01519427 | Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2014 | clinicaltrials |
| NCT00087373 | Vaccine Therapy in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Jun 9, 2014 | clinicaltrials |
| NCT00671554 | Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma | terminated | Phase 1 / Phase 2 | 3 | Prisma Health-UpstateOTHER | 1 | Jun 4, 2014 | clinicaltrials |
| NCT01068470 | Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy(LAK) | terminated | — | 11 | Loma Linda UniversityOTHER | 1 | May 29, 2014 | clinicaltrials |
| NCT00005841 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | terminated | Phase 1 | 15 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00006113 | Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma | terminated | Phase 2 | 25 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00184067 | Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma | terminated | Phase 2 | 23 | University of Southern CaliforniaOTHER | 1 | May 21, 2014 | clinicaltrials |
| NCT01166126 | Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT00522834 | Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma | terminated | Phase 3 | 630 | Synta Pharmaceuticals Corp.INDUSTRY | 8 | Mar 4, 2014 | clinicaltrials |
| NCT01055522 | Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma | terminated | Phase 2 | 102 | Philogen S.p.A.INDUSTRY | 4 | Feb 25, 2014 | clinicaltrials |
| NCT00402662 | A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma | terminated | Phase 2 | 3 | Yale UniversityOTHER | 1 | Dec 18, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jun 24, 2016source: clinicaltrials